Photo taken from IASLC/X
May 2, 2024, 14:14
Stephen V Liu discusses KRAS mutant NSCLC with Veluswamy and Mariana Brandao – IASLC
International Association for the Study of Lung Cancer (IASLC) shared on X:
“KRAS mutations are common in lung cancer, and while there are multiple approved/active KRAS inhibitors, they are specifically for the G12C mutation. Stephen V Liu discusses KRAS mutant Non-Small Cell Lung Cancer (NSCLC) with focus on non-G12C mutations with Veluswamy and Mariana Brandao.”
Additional information.
Source: IASLC/X